EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+3.9%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$966M
AUM Growth
+$966M
(+5.6%)
Cap. Flow
-$36.3M
Cap. Flow
% of AUM
-3.75%
Top 10 Holdings %
Top 10 Hldgs %
72.41%
Holding
47
New
16
Increased
6
Reduced
13
Closed
2
Top Buys
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$45.7M |
| 2 |
AKCA
Akcea Therapeutics, Inc. Common Stock
AKCA
|
$26.4M |
| 3 |
CRISPR Therapeutics
CRSP
|
$22.2M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$19.4M |
| 5 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$14.2M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$55.8M |
| 2 |
Traws Pharma
TRAW
|
$51.4M |
| 3 |
Ascendis Pharma
ASND
|
$26.7M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
$20.5M |
| 5 |
Sangamo Therapeutics
SGMO
|
$19.8M |
Sector Composition
| 1 | Healthcare | 88.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
FibroGen
FGEN
$47.8M
| $123M | 11.04% | 2,017,250 | – | – |
|
2
Assembly Biosciences
ASMB
$190M
| $109M | 9.85% | 2,943,164 | – | – |
|
|
3
Ironwood Pharmaceuticals
IRWD
$214M
| $94.9M | 8.55% | 5,141,624 -1,108,449 | -18% | -$20.5M |
|
|
4
Ascendis Pharma
ASND
$11.8B
| $77M | 6.94% | 1,087,257 -376,810 | -26% | -$26.7M |
|
5
Kura Oncology
KURA
$686M
| $68.3M | 6.15% | 3,902,975 -1,700 | -0% | -$29.8K |
|
6
Scholar Rock
SRRK
$3.14B
| $61M | 5.49% | 2,367,378 -303,783 | -11% | -$7.82M |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $58M | 5.23% | 3,802,327 +841,180 | +28% | +$12.8M |
|
|
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $45.7M | 4.11% | +837,048 | New | +$45.7M |
|
9
MacroGenics
MGNX
$112M
| $31.8M | 2.86% | 1,481,086 +30,480 | +2% | +$653K |
|
10
Arcus Biosciences
RCUS
$1.13B
| $31.2M | 2.81% | 2,236,387 | – | – |
|
11
Kezar Life Sciences
KZR
$28.9M
| $27.6M | 2.48% | 1,288,198 +16,000 | +1% | +$343K |
|
|
AKCA
12
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $26.4M | 2.38% | +755,120 | New | +$26.4M |
|
|
13
CRISPR Therapeutics
CRSP
$4.71B
| $22.2M | 2% | +500,000 | New | +$22.2M |
|
|
14
Ultragenyx Pharmaceutical
RARE
$2.89B
| $19.4M | 1.75% | +254,000 | New | +$19.4M |
|
15
Dianthus Therapeutics
DNTH
$759M
| $18.5M | 1.66% | 1,538,088 | – | – |
|
|
UBX
16
DELISTED
Unity Biotechnology
UBX
| $15.8M | 1.42% | 967,114 -713,530 | -42% | -$11.6M |
|
|
SURF
17
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $14.9M | 1.34% | 1,363,479 +472,671 | +53% | +$5.17M |
|
|
RUBY
18
DELISTED
Rubius Therapeutics, Inc
RUBY
| $14.2M | 1.28% | +592,128 | New | +$14.2M |
|
|
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $12.5M | 1.12% | 1,039,500 | – | – |
|
20
Arbutus Biopharma
ABUS
$711M
| $11.6M | 1.05% | +1,231,800 | New | +$11.6M |
|
21
Spero Therapeutics
SPRO
$116M
| $9.38M | 0.85% | +892,741 | New | +$9.38M |
|
|
IMDZ
22
DELISTED
Immune Design Corp.
IMDZ
| $7.74M | 0.7% | 2,241,900 -2,195,700 | -49% | -$7.58M |
|
23
Zai Lab
ZLAB
$3.68B
| $6.82M | 0.61% | +350,000 | New | +$6.82M |
|
24
Neurogene
NGNE
$264M
| $6.64M | 0.6% | 2,265,880 +1,115,880 | +97% | +$3.27M |
|
25
Elanco Animal Health
ELAN
$9.12B
| $6.63M | 0.6% | +190,000 | New | +$6.63M |
|